BUDZ · Weed, Inc.
$0.02
0.00 (-0.45%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$2.97M
Shares
148.31M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$1.37M
-168.7%
FY2025
Diluted EPS
-$0.01
-150%
FY2025
Operating Cash Flow
-$195.14K
+53%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | — | — | |
| — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $129.22K | $40.19K | |
| $812.66K | $1.13M | $351.12K | $394.62K | $567.16K | $797.68K | $313.92K | $969.91K | $1.36M | $671.68K | $6.9M | $420.54K | |
| — | $2600 | $2600 | $2460 | $2460 | $2524 | $2817 | $2600 | $1484 | $0 | — | — | |
| $22.49K | $22.49K | $22.59K | $52.39K | $111.43K | $129.79K | $145.8K | $159.42K | $180.64K | $44.65K | $8071 | $1760 | |
| $1.06M | $1.33M | $529.99K | $770.57K | $1.51M | $2.8M | $4.08M | $27.42M | $28.41M | $2.38M | $7.16M | $494.14K | |
| -$1.06M | -$1.33M | -$529.99K | -$770.57K | -$1.51M | -$2.8M | -$4.08M | -$27.42M | -$28.41M | -$2.38M | $7.16M | $494.14K | |
| -$1.03M | -$1.31M | -$507.41K | -$718.18K | -$1.39M | -$2.67M | -$3.93M | -$27.26M | -$28.22M | -$2.34M | $7.17M | $495.9K | |
| — | — | $5070 | $45.27K | $117.12K | $39.24K | $40.83K | $11.67K | $12.18K | $13.87K | -$21.02K | -$3500 | |
| — | -$44.49K | -$50.33K | $739.99K | -$22.83K | -$40.47K | $11.4K | -$112.61K | -$909.39K | -$1.1M | $21.02K | $3500 | |
| -$1.11M | -$1.37M | -$510.32K | — | -$1.53M | -$2.84M | -$4.07M | — | — | — | — | — | |
| $33 | $33 | $399 | $980 | $0 | — | — | — | — | — | — | — | |
| -$1.11M | -$1.37M | -$510.72K | -$31.56K | -$1.53M | -$2.84M | -$4.07M | -$27.53M | -$29.32M | -$3.48M | $7.18M | $497.64K | |
| -$1.11M | -$1.37M | -$509.92K | -$25.98K | -$1.53M | -$2.84M | -$4.06M | -$27.53M | -$29.32M | — | — | — | |
| USD/shares | — | — | -$0.00 | -$0.00 | -$0.01 | -$0.02 | — | — | — | — | — | — |
| USD/shares | — | -$0.01 | -$0.00 | -$0.00 | — | — | — | — | — | — | — | — |
| shares | — | — | 124.13M | 123.71M | 122.08M | 116.73M | 112.22M | 107.65M | 103.17M | 101.21M | — | — |
| shares | — | 135.92M | 124.13M | 123.71M | — | 116.73M | 112.22M | 107.65M | 103.17M | 101.21M | 12.13M | 11.26M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 26.04×
Peer medians compare against the 22 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).